Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Beloranib

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Zafgen · Phase 2 · Completed · Enrollment 17

NCT01818921

ArmPopulationDoseWeeksEstimandWeight change
ZGN-440 sterile diluentObesity or overweightn/r4n/rn/r
1.2 mg ZGN-440 for injectable suspensionObesity or overweight1.2 mg4n/rn/r
1.8 mg ZGN-440 for injectable suspensionObesity or overweight1.8 mg4n/rn/r